Quantcast
Last updated on April 19, 2014 at 7:35 EDT

Resverlogix Completes Dosing of RVX-208 in SUSTAIN, a Phase 2b Clinical Trial Targeting High-Risk Cardiovascular Disease Patients

May 9, 2012

TSX Exchange Symbol: RVX

CALGARY, May 9, 2012 /PRNewswire/ – Resverlogix Corp. (TSX:RVX) is pleased to
announce that dosing in SUSTAIN, a Phase 2b clinical trial to assess
lipid trends and safety of RVX-208, has been completed on schedule. All
patients in the Cleveland Clinic led trial had significant
cardiovascular disease (CVD) risks.

In SUSTAIN, a 24-week, multi-centered, double-blind, randomized,
parallel group, placebo controlled trial, all subjects received
standard of care therapy including up to 40 mg atorvastatin (Lipitor)
or 20 mg rosuvastatin (Crestor). As recently stated, RVX-208 is the
first known BET Bromodomain inhibitor to be studied in humans. It is an
orally active small molecule that raises ApoA-I production leading to
enhanced reverse cholesterol transport (RCT).  SUSTAIN trial subjects
received either RVX-208 (200 mg/day) or placebo for 24 weeks for the
purposes of studying a panel of lipid parameters versus baseline. 
SUSTAIN is an important component of an expanded clinical program that
includes a parallel Phase 2b clinical trial, ASSURE.  The ASSURE trial
will utilize intravascular ultrasound (IVUS) to study the important
atherosclerotic plaque regressing aspects of RCT. The unique mechanism
by which RVX-208 can potentially regress atherosclerotic plaque
distinguishes it from all other known drug classes or small molecule
candidates in clinical development.  Resverlogix expects to report top
line data for SUSTAIN in Q3 2012 and for ASSURE in Q1 2013.

“We have completed dosing in the SUSTAIN trial, right on schedule,”
stated Donald McCaffrey, president and chief executive officer of
Resverlogix. “Data from this trial will be used to assess the safety
and efficacy of RVX-208 in a high-risk population with CVD. This
population provides an ideal opportunity to test the effects of
RVX-208.  We are particularly interested in confirming the safety of
RVX-208 in the extended dosing time frame from three to six months.”

Allan Gordon, M.D., Ph.D. and senior vice president of clinical
development at Resverlogix, added, “the SUSTAIN trial extends the
duration of clinical exposure to RVX-208 by 3 months. Not only will
this data provide us with important insights into the safety and
efficacy of RVX-208, we also expect important new information for the
future development of RVX-208.”

About RVX-208
RVX-208 is a novel small molecule that targets and inhibits BET
Bromodomains. It is the first small molecule of this novel class of
compounds in clinical development.  RVX-208 stimulates endogenous
ApoA-I production leading to enhanced reverse cholesterol transport
(RCT). The main role of ApoA-I is to assist the body’s natural defense
system against atherosclerosis as ApoA-I performs its function in a
normal physiologic process called RCT. This pathway enables
cholesterol, including that within atherosclerotic plaques of vessel
walls, to be transported to the liver for further processing and
elimination from the body.  Enhanced RCT clearance of cholesterol from
vessel walls should reduce or prevent atherosclerosis. The ability of
RVX-208 to increase ApoA-I production to augment RCT is  a highly
differentiated approach from all other CVD therapies. RVX-208 is
positioned to be one of the most promising drugs in development for the
treatment of atherosclerosis.

About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in the
development of novel therapies for important global medical markets
with significant unmet medical needs. The NexVas(TM) Plaque Regression
program is our primary focus which is to develop novel small molecules
that enhance ApoA-I production and remove atherosclerotic plaque. These
vital therapies are focused to address the burden of atherosclerosis
and other important diseases such as Acute Coronary Syndrome,
Alzheimer’s disease, Peripheral Artery Disease, Oncology and Autoimmune
diseases. Resverlogix’ common shares trade on the Toronto Stock
Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking information as
defined under applicable Canadian securities legislation, that are not
based on historical fact, including without limitation statements
containing the words “believes”, “anticipates”, “plans”, “intends”,
“will”, “should”, “expects”, “continue”, “estimate”, “forecasts” and
other similar expressions. In particular, this news release includes
forward looking information relating to research and development
activities, the conduct of the SUSTAIN trial and the potential role of
RVX-208 in the treatment of atherosclerosis. Our actual results, events
or developments could be materially different from those expressed or
implied by these forward-looking statements. We can give no assurance
that any of the events or expectations will occur or be realized. By
their nature, forward-looking statements are subject to numerous
assumptions and risk factors including but not limited to those
associated with the success of research and development programs,
clinical trial programs including possible delays in patient
recruitment, the regulatory approval process, competition, securing and
maintaining corporate alliances, market acceptance of the Company’s
products, the availability of government and insurance reimbursements
for the Company’s products, the strength of intellectual property,
financing capability, the potential dilutive effects of any financing,
reliance on subcontractors and key personnel and additional assumptions
and risk factors discussed in our Annual Information Form and most
recent MD&A which are incorporated herein by reference and are
available through SEDAR at
www.sedar.com. The forward-looking statements contained in this news release are
expressly qualified by this cautionary statement and are made as of the
date hereof. The Company disclaims any intention and has no obligation
or responsibility, except as required by law, to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.

For further information, please contact:


    Company Contacts:

    Donald J. McCaffrey                                            Sarah Zapotichny
    President and CEO                                              Director of Investor Relations
    Resverlogix Corp.                                              Resverlogix Corp.
    Phone: 403-254-9252                                            Phone: 403-254-9252
    Email:                                                         Email:
    don@resverlogix.com   sarah@resverlogix.com

    US Institutional Investors:                                    Media:

    Susan Noonan                                                   Tony Russo, Ph.D.
    Managing Partner                                               Matt Middleman, M.D.
    S.A. Noonan Communications, LLC                                Russo Partners, LLC
    Phone: 212-966-3650                                            Phone: 212 845 4251
    Email:                                                         Phone: 212-845-4272
    susan@sanoonan.com     Email: tony.russo@russopartnersllc.com
                                                                   Email:
                                                                   matt.middleman@russopartnersllc.com

SOURCE Resverlogix Corp.


Source: PR Newswire